Evidence map›Paper›PMID 41431747›Full record

ArticleEuropean journal of preventive cardiology2026

The role of inflammation in longitudinal renal function decline and incident chronic kidney disease: the multi-ethnic study of atherosclerosis.

Olayinka J Agboola, Jeffrey S K Chan, Jared A Spitz, Raymond N C Chan, Jaideep Patel, Charles German, Khurram Nasir, Michael J Blaha, Anurag Mehta, Garima V Sharma and 1 more

Abstract readMulticenter Study
In one paragraph

Article in European journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Olayinka J AgboolaInova Schar Heart and Vascular, Inova Health System, Falls Church, VA, USA.ORCID 0000-0003-1793-4734
Jeffrey S K ChanCardiovascular Analytics Group, China-UK Collaboration, Hong Kong, China.
Jared A SpitzInova Schar Heart and Vascular, Inova Health System, Falls Church, VA, USA.
Raymond N C ChanDepartment of Medicine and Therapeutics, Prince of Wales Hospital, New Territories, Hong Kong, China.
Jaideep PatelCiccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Charles GermanSection of Cardiology, Medstar Georgetown University Hospital, Washington, DC, USA.
Khurram NasirSection of Cardiology, Houston Methodist, Houston, TX, USA.
Michael J BlahaSchool of Biomedical Sciences, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong, China.
Anurag MehtaVCU Health Pauley Heart Center, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Garima V SharmaInova Schar Heart and Vascular, Inova Health System, Falls Church, VA, USA.
Michael D ShapiroCenter for Prevention of Cardiovascular Disease, Department of Cardiology, Wake Forest University School of Medicine, Bowman Gray Center for Medical Education, 475 Vine Street, Winston-Salem, NC 27101, USA.ORCID 0000-0002-9071-3287

Funding

Task Area A Core Study Operations.Task Area A shall encompass annual follow-up of cohort members, clinical endpoints ascertainment, study coordination activities, maintenance of the database and biosp75N92020D00001 · NHLBI · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, ROBYN LEAGH · 2020 to 2025
$17.2M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
TO EXERCISE OPTION PERIOD ONE (1) FOR TASK AREA A - MESA CORE OPERATIONS, FIELD CENTER.75N92020D00004 · NHLBI · NORTHWESTERN UNIVERSITY · PI SIEGEL, JONATHAN H · 2020 to 2025
$4.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00006 · NHLBI · UNIVERSITY OF MINNESOTA · PI PANKOW, JAMES S · 2020 to 2025
$4.4M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00003 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI POST, WENDY S · 2020 to 2025
$3.8M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00007 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BERTONI, ALAIN GERALD · 2020 to 2025
$3.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00002 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEA, STEVEN J · 2020 to 2025
$3.4M
MESAMESA investigatorsMESA investigators DK063491MESA investigators N01-HC-95159MESA investigators N01-HC-95160MESA investigators N01-HC-95161MESA investigators N01-HC-95162MESA investigators N01-HC-95163MESA investigators N01-HC-95164MESA investigators N01-HC-95165MESA investigators N01-HC-95166MESA investigators N01-HC-95167MESA investigators N01-HC-95168MESA investigators N01-HC-95169MESA investigators R01HL105756MESA investigators UL1-TR-000040MESA investigators UL1-TR-001079MESA investigators UL1-TR-001420MESA investigators UL1TR001881Multi-Ethnic Study of AtherosclerosisNHLBI NIH HHSNHLBI NIH HHS 75N92020D00001NHLBI NIH HHS 75N92020D00002NHLBI NIH HHS 75N92020D00003NHLBI NIH HHS 75N92020D00004NHLBI NIH HHS 75N92020D00005NHLBI NIH HHS 75N92020D00006NHLBI NIH HHS 75N92020D00007NHLBI NIH HHS HHSN268201500003I
6 · The paper itself

Abstract

aimsChronic inflammation has been implicated in renal decline, but long-term population-based data are limited. We aimed to evaluate the associations between baseline inflammatory markers [interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP)] and long-term renal function decline and incident chronic kidney disease (CKD). METHODS AND

resultsThis prospective cohort study included participants of the Multi-Ethnic Study of Atherosclerosis (MESA) with estimated glomerular function (eGFR) > 60 mL/min/1.73 m2 and available IL-6 and hsCRP measurements at visit 1. Outcomes included longitudinal changes in eGFR and log-transformed urinary albumin-creatinine ratio [log(UACR)] through visit 5, and incident CKD through 2018. Mixed-effect linear regression models assessed renal function decline. Fine-Gray regression was used to model incident CKD, accounting for competing mortality. Among 4680 (hsCRP) and 4580 (IL-6) participants (median follow-up for incident CKD: 16.8 years), higher IL-6 was consistently associated with faster eGFR decline [tertile 3 (T3; vs. T1): -0.32 mL/min/1.73m2/year (95% CI: 0.23-0.42 mL/min/1.73m2/year), P < 0.001] greater log[UACR] increase [T3: 6.67 × 10-3 unit/year (2.95 × 10-3-10.39 × 10-3 unit/year), P < 0.001], and higher CKD incidence [T3: sub-hazard ratio 1.65 (1.23-2.20), P = 0.001]. Contrastingly, hsCRP exhibited weaker and inconsistent associations.

conclusionElevated IL-6 predicts greater long-term eGFR decline, worsening albuminuria, and higher CKD risk. These results highlight IL-6's potential as a renal risk biomarker, meriting further study in cardiovascular-kidney-metabolic (CKM) syndromes. LAY SUMMARY: This study investigated how inflammation is related to deteriorations in kidney function and the occurrence of chronic (long-term) kidney disease (CKD), both of which are critical components of the cardiovascular-kidney-metabolic (CKM) syndrome. Using data from the Multi-Ethnic Study of Atherosclerosis, over 4500 volunteers had inflammation markers measured and were followed for almost 17 years. We found that higher levels of inflammation were correlated with worse deterioration in kidney function and higher risks of developing CKD. These findings reaffirmed the pivotal role of inflammation in the long-term development of kidney disease. This study highlights the need for further investigation of how inflammatory markers can be used to predict future heart and kidney disease, especially as new drugs to treat inflammation are being developed.

Indexed as

AtherosclerosisGlomerular Filtration RateInflammationInflammation MediatorsInterleukin-6KidneyRenal Insufficiency, ChronicAgedBiomarkersC-Reactive ProteinDisease ProgressionFemaleHumansIncidenceLongitudinal StudiesMaleBiomarkersC-Reactive ProteinIL6 protein, humanInflammation MediatorsInterleukin-6chronic kidney diseaseCKM syndromeC-reactive proteinInflammationInterleukin-6

Identifiers

PMID41431747
PMCPMC13021255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.